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Chemotherapy is the main treatment for small-cell lung cancer
(SCLC), one of the solid tumours which responds best to cyto-
toxic agents, and survival benefit has been widely demonstrated
(Hansen et al, 1991). Various drug combinations have been used in
sequential chemotherapies in order to improve both response rate
and survival. Among these combinations, cisplatin and etoposide
(Ihde et al, 1984; Maksymiuk et al, 1994; Evans et al, 1985) or
cyclophosphamide, doxorubicin and vincritine (Feld et al, 1989)
are two widely applied regimens inducing a 80–90% overall
response rate including a 30–40% complete response rate. Despite
the high chemosensitivity of SCLC, the 2- and 5-year survivals are
low due to the frequent occurrence of chemoresistant relapses after
these classical regimens. In SCLC, relapses are presumed to be
have a relationship with the lack of efficiency of the induction
treatment which selects sub-clones of the tumour sharing genetic
resistance to cytotoxic agents. The search to improve the SCLC
chemotherapy outcome aims to circumvent these secondary
chemoresistances. Optimal chemotherapy drug combinations and
schedules therefore remain to be established.
Cisplatin (cis-diamine-dichloroplatinum II [N2Cl2PtH6]) is a
planar inorganic heavy metal compound yielding alkylating proper-
ties (Rosenberg et al, 1965). It does not possess a cell-cycle depen-
dency and is active throughout the cell cycle. This cytotoxic agent is
a pivotal drug in the treatment of many human malignancies such as
non-seminomatous germinal cell tumour (Einhorn and Donohue,
1977), lymphoma (Rossof et al, 1972) and ovarian cancer (Wiltshaw
and Kroner, 1976). In non-small-cell lung cancer (NSCLC),
randomized trials have suggested that cisplatin might also be an
important drug. For instance, in stage III NSCLC, meta-analysis 
of randomized studies comparing a chemotherapy–radiotherapy
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Summary Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug combinations and schedules remain to be
defined and there is hitherto no world-wide accepted standard regimen. Cisplatin, an alkylating agent with high putative toxicity is currently
widely used although its effectiveness in this disease has not been established firmly. We conducted a meta-analysis of published data
reporting trials randomizing a cisplatin-containing regimen versus a regimen without this alkylating agent in order to determine possible
differences in survival response and toxicity. Nineteen trials have been identified in medical literature (4054 evaluable patients). Ten trials
randomized patients to receive a cisplatin-etoposide regimen versus a regimen without any of these two drugs. A subgroup analysis was,
therefore, carried out in the nine remaining trials that randomly allocated patients between two regimens differing in the absence or presence
of cisplatin, whereas etoposide was given (or not given) in both arms (1579 evaluable patients). The DerSimonian and Laird method was used
to estimate the size effects and the Peto and Yusuf method was used in order to generate the odds ratios (OR) of reduction in risk of death
and the increase in probability of being responders to chemotherapy. There was no significant difference between the cisplatin-containing
regimen and the regimen without this drug when the risk of toxic-death was taken into account with respective probabilities of 3.1 and 2.7%
(NS). Patients randomized in a cisplatin-containing regimen had an increase in probability of being responders with an OR of 1.35, 95%
confidence interval (CI) of 1.18–1.55; P < 10–5 corresponding to an increase of objective (partial plus complete) response rate from 0.62 to
0.69 (a result taking into account a significant heterogeneity). Patients treated with a cisplatin-containing regimen benefited from a significant
reduction of risk of death at 6 months and 1 year with respective OR 0.87, 95% CI 0.75–0.98, P = 0.03, and or 0.80, 95% CI 0.69–0.93, 
P = 0.002 (no statistical heterogeneity). This corresponded to a significant increase in the probability of survival of 2.6% and 4.4% at 6 months
and 1 year respectively. The meta-analysis restricted to the subset of nine trials without etoposide treatment imbalance reached similar
conclusions. A cisplatin-containing regimen yields a higher response rate and probability of survival than does a chemotherapy containing
others alkylating agents without a perceptible increase in risk of toxic-death. © 2000 Cancer Research Campaign
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Belgiumcombination versus radiotherapy alone has demonstrated that the
combined modality treatment reduces the risk of death. This effect is
particularly apparent where the chemotherapy is based on a modern
combination. It is noteworthy that the break between older and more
modern regimens coincided with the introduction of cisplatin in
NSCLC chemotherapy (Non-Small Cell Lung Cancer Collaborative
Group, 1995). Although chemotherapy is supposed to yield a better
survival impact in SCLC than in NSCLC, the role of cisplatin in the
former histology is still unclear.
In SCLC, cisplatin is widely used although its role in improving
patient survival has not been firmly established. As this drug also
yields a putatively high toxicity (mainly nephrotoxicity, ototoxi-
city and emesis), it might be of interest to determine whether or not
the use of cisplatin is supported by evidence of effectiveness in
SCLC.
A meta-analysis of published randomized trials comparing a
cisplatin-containing regimen with a combination without cisplatin
was made in an attempt at determining whether or not this alky-
lating agent improves response and survival.
TRIALS AND METHODS
Eligibility criteria
To be included in this meta-analysis, trials fulfilled the following
criteria; randomized trials involving previously untreated and
histologically or cytologically proven SCLC patients with com-
prehensible randomization methods (particularly allocation
concealment); randomized allocation of patients between a
cisplatin-containing regimen and a regimen without this alkylating
agent. Trials comparing an alternating approach of two chemother-
apies one of them containing cisplatin versus a single regimen
without cisplatin were also eligible. Studies comparing a cisplatin-
containing regimen to chemotherapy based upon another platinum
cytotoxic agents (particularly carboplatin) were not eligible. In
addition to the above-mentioned key criteria, a number of quality-
control items of publication were taken into account, in particular
definition of hypothesis in the statistics section of each article,
definition of the patients’ characteristics in regard to fundamental
prognostic factors (sex, performance index, stage of the disease),
definition of the treatment protocol and drug dosage reduction
procedures and definition of survival. Trials were also screened
regarding the report of the number of evaluable patients, response
assessment procedure and toxicity, particularly toxic deaths.
Finally, the lack of confusing additional variables such as imbal-
ance of radiotherapy between the two regimens and the number of
patients lost to follow-up were checked.
Selections of trials
A computerized bibliography was extracted from MEDLINE and
CANCERLIT (CancerNet™) databases using medical subject
headings of the following terms: lung neoplasm, small-cell cancer,
randomized trials, chemotherapy, cisplatin or cisplatinum or cis-
diamine-dichloroplatinum. The search was carried out from 1966
to the end of 1999 inclusive. Afterwards, the manual selection of
relevant trials was based upon summary analysis. In addition to the
above-mentioned procedure, bibliographies of selected full papers
were screened in order to disclose other relevant articles and
SCLC experts were consulted about the topic in order to make the
meta-analysis as exhaustive as possible. We did not disclose any
unpublished trial matching the selection criteria.
Collection of data
The following general items were recorded: year of publication,
hypothesis, method of randomization and method of analyses
(intent to treat or fully-eligible population). In addition, the
following variables were recorded for each arm of treatment:
number of accrual patients, number of eligible patients, number of
patients lost to follow-up, mean age, sex ratio, proportion of
patients with good performance status (0 or 1), extensive versus
limited disease stage. Regarding treatment design we input the
precise drugs in each arm, and in the cisplatin-containing regimen,
the planned dose-intensity for this drug in mg m–2 week–1. Finally,
the number of patients receiving thoracic radiotherapy was also
recorded.
The outcome of the meta-analysis for each treatment arm was
assessed as follows: number of toxic-deaths (other toxicities not
having been homogeneously reported), percentage of patients
achieving a partial or complete response, overall survival at 6
months and 1 year. The latter two parameters were directly graph-
ically measured from magnifications of publication graphs. When
the data were directly reported in the text, comparisons with
graphic assessment were in good agreement. An attempt to contact
the first author of each selected article was made in order to obtain
authorization to use the data and to know whether there has been
any update of the trial following its publication. Unfortunately, due
to the change in position of several colleagues this could not be
achieved exhaustively.
Statistical analysis
Two methods were used in order to estimate the effects of cisplatin
on survival, response and toxicity of SCLC patients. The Yusuf
and Peto method produces odds ratio (OR) and its 95% confidence
interval (CI) together with the value of the heterogeneity test
(Yusuf et al, 1985). In addition, the DerSimonian and Laird
method was used in order to estimate the size effects upon the
different parameters and their 95% CIs were calculated
(DerSimonian and Laird, 1986). For this method the value and the
95% CI were corrected taking into account the heterogeneity
where this latter parameter was statistically significant.
RESULTS
A total of 19 trials fulfilled the criteria of selection (Table 1; Eagan
et al, 1981; Fukuoka et al, 1986, 1991; Evans et al, 1987; Haveman
et al, 1987; Wolf et al, 1987; Chahinian et al, 1989; Sculier et al,
1990a, 1993; Goodman et al, 1990; Smith et al, 1990; Wampler et al,
1991; Kanitz et al, 1992; Roth et al, 1992; Farris et al, 1993;
Sculier et al, 1993; Joss et al, 1994; Veronesi et al, 1994; Souhami
et al, 1997; Urban et al, 1999). One trial was rejected due to the
fact that patients had received chemotherapy prior to randomiza-
tion as it was a second-line chemotherapy study (O’Bryan et al,
1990). A total of 4054 eligible patients were randomized between
a cisplatin-containing regimen (1814 patients) and a regimen
without cisplatin (2240 patients). Since the beginning of the 1980s
it has been hypothesized that the cisplatin–vepeside combination
generates a synergistic activity. Some studies selected for the
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.meta-analysis actually randomized patients between a cisplatin–
vepeside combination (sometimes included in an alternating
chemotherapy programme) versus a regimen with neither of these
two drugs. Thus for these trials there was a vepeside administra-
tion imbalance between the two regimens. Therefore, a subset
meta-analysis was made for the nine studies without vepeside
imbalance (i.e. vepeside administered similarly in both arms or not
given in either arm). These trials included 1579 evaluable patients
(Eagan et al, 1981; Wolf et al, 1987; Goodman et al, 1990; Sculier
et al, 1990a1993; Smith et al, 1990, Kanitz et al, 1992; Joss et al,
1994; Souhami et al, 1997).
Toxicity
Data regarding neutropenic infections, nephrotoxicity and ototoxi-
city were not reported homogeneously among the different trials.
On the other hand, the number of toxic-deaths was clearly reported
by 16 out of the 19 trials. Therefore, we focused on the percentage
of patients affected by a toxic-death. Patients treated with a
cisplatin-containing regimen were not at higher risk of toxic death
than patients treated with a regimen without this alkylating 
agent with respective probabilities of 0.031 and 0.027 and a size
effect of 0.004 according to the DerSimonian and Laird method
(Table 2).
Response
Patients who had received a cisplatin-containing regimen proved
to have a higher probability of being responders in comparison
with patients included in a regimen without cisplatin, with an OR
(95% confidence interval (CI)) of 1.35 (95% CI 1.18–1.55); 
P< 10–5. This result corresponded to an OR of being non-
responder of 0.74 (95% CI 0.85–0.64) for patients receiving
cisplatin-containing regimens (Figure 1). With these regimens, the
DerSimonian and Laird method measured a significant 
(P< 0.0001) increase in response rate from 0.62 to 0.69 taking into
account a significant heterogeneity (Q = 51.08; degree of freedom:
18: P< 0.05).
Survival
Patients treated with a cisplatin-containing regimen proved to have
a lower risk of death in comparison with patients treated by a
regimen without cisplatin at 6 months and 1 year with a respective
OR of 0.87 (95% CI 0.75–0.98); P= 0.03 (Figure 2) and OR 0.80
(95% CI 0.69–0.93); P= 0.002 (Figure 3) without statistical
heterogeneity. The corresponding survival rates at 6 months were
0.68 and 0.65 for the former and latter type of chemotherapy 
as measured by the DerSimonian and Laird method. These rates
were 0.29 and 0.24 at 1 year l 2). This corresponded to a
significant increase in the probability of survival of 2.6% and 4.4%
at 6 months and 1 year respectively.
Subgroup analysis in trials without vepeside imbalance
Nine trials without vepeside administration imbalance between the
cisplatin-containing regimen and the regimen without cisplatin
were meta-analysed and the size effects measured using the
DerSimonian and Laird method (Table 3). All conclusions drawn
from the meta-analysis of the whole selection of trials were also
applicable to this subset analysis. In particular, patients receiving a
cisplatin-containing regimen proved to have a lower risk of death
at 6 months with an OR of 0.74 (95% CI 0.59–0.94); P = 0.006. At
1 year the OR was 0.80 (95% CI 0.63–0.98); P = 0.03. The
DerSimonian and Laird method showed a significant 4.4%
survival benefit at 6 months and 4.1% at 1 year in favour of the
cisplatin-containing regimen (Table 3). The OR of being a
responder in a cisplatin-containing regimen was 1.48 (95% CI
1.18–1.87);  P = 0.01.
DISCUSSION
In this meta-analysis, the putative benefits of a cisplatin regimen
were analysed in a selection of trials comparing a cisplatin-
containing regimen and chemotherapy based on other alkylating
agents. Patients receiving a cisplatin regimen proved to have a
better probability of being responders, and a better survival. These
effects were of moderate size. However, no detectable increase in
the risk of toxic death was disclosed.
It is widely accepted that prognosis of SCLC is improved by
chemotherapy (Hansen et al, 1991). Combination chemotherapy
was the main treatment in the 1970s. Multiple drug combinations
led to a longer survival than single drug treatment or radiation-
therapy alone. Among the active drugs in SCLC, cyclophos-
phamide–adriamycin–vincristine (Fukuoka et al, 1986; Feld et al,
1989) or cyclophosphamide–adriamycin–etoposide combinations
have long been known as having a good efficacy/toxicity ratio.
Other combination chemotherapies such as cisplatin and etopo-
side have been tested successfully and have given encouraging
results in terms of both response and survival rates (Ihde et al,
1984; Maksymiuk et al, 1994; Evans et al, 1985). It rapidly
appeared that response to chemotherapy is one of the most impor-
tant factors for SCLC patients to achieve long-term survival
(Osterlind et al, 1986) in association with other known favourable
prognostic factors, namely limited disease, good performance
status, lower age group, low serum lactate dehydrogenase, low
alkaline phosphatases and normal serum sodium and bicarbonate
(Cerny et al, 1987). Other investigators have demonstrated 
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Table 2 Results of DerSimonian and Laird meta-analysis of trials of cisplatin containing regimen versus a regimen without cisplatin
Cisplatin-containing Regimen without Yb Y: 95% confidence P Heterogeneity Degrees of p heterogeneity
regimen (Probability) cisplatin (Probability) interval freedom
Toxic death rate 0.031 0.027 0.004 –0.007–0.016 0.23 Q=15.37 15 0.41
Response rate 0.688 0.619 0.070a 0.021–0.125a <0.0001 Q=51.08 18 0.001
Survival at 6 months 0.684 0.658 0.026 0.001–0.055 0.030 Q=22.28 18 0.22
Survival at 1 year 0.288 0.244 0.044 0.0016–0.072 0.0009 Q=25.85 18 0.15
a Corrected value taking into account a significant heterogeneity. b Size effect according to the DerSimonian and Laird method.that the cisplatin–etoposide combination is efficient as a rescue
treatment for patients who relapsed after cyclophosphamide–
adriamycin–vincristine, by inducing a 50% response rate in these
poor conditions of second-line treatment (Evans et al, 1985;
Porter et al, 1985). Conversely, patients previously treated with
cisplatin–etoposide might respond to cyclophosphamide–adri-
amycin–vincristine combination, although in a lower proportion
(10–20%) (Sculier et al, 1990b). This indirect comparison
suggests a superiority of the cisplatin-based regimen. The meta-
analysis presented here adds another clue in favour of the early
use of cisplatin in the course of SCLC.
One may hypothesize that, due to the nature of the herein meta-
analysis based on published data, a possible bias was introduced
insofar as our procedure did not allow the disclosure of unpub-
lished trials. A direct comparison of meta-analysis on medical liter-
ature and meta-analysis on individual patient data has been
performed in the setting of cisplatin-based chemotherapy in ovarian
cancer (Stewart and Parmar, 1993). This study suggested possible
differences in estimated treatment effect due to patient exclusions
and shorter length of follow-up in the former technique. On the
other hand, regarding survival, which was the main outcome of our
meta-analysis, there was no statistical heterogeneity. In addition,
there was no apparent effect of epoch when year of publication was
taken into account. In particular, considering the 1-year survival
outcome, four trials did not detect any difference between the two
types of treatment, three others were able to demonstrate the statis-
tical benefit conferred by a cisplatin-based regimen, whereas the
remaining 12 trials suggested a trend (nine in favour of cisplatin
containing regimens and three in favour of chemotherapy without
this alkylating agent). The results of the meta-analysis are therefore
in agreement with a qualitative analysis of the literature which was
in favour of the beneficial effect of cisplatin.
Vepeside–cisplatin has been widely used since the 1980s as a
control regimen owing to the putative synergy of this combination.
We therefore investigated whether or not the cisplatin benefit such
as it was observed in the whole selection of trials was linked to the
synergistic action of the cisplatin–vepeside combination. 
As shown by the subset analysis made in the subgroup of 
nine trials without vepeside imbalance, cisplatin-containing 
regimens shared an advantageous effect on both survival and
response. Thus, the administration of cisplatin seems to result 
in an improvement of outcome as a result of its administration 
per se.
Finally, our meta-analysis did not include any trial involving a
carboplatin-containing regimen. This choice was made for two
reasons: first, carboplatin yields a different pattern of toxicity,
resulting in a putative difference in combination effect; secondly,
randomized trials involving this drug administered in one arm
only, mainly compared carboplatin with cisplatin. Thus, our
conclusions apply to cisplatin only and cannot be extended to
other platinum agents.
Although modest, the survival improvement observed in
cisplatin-containing chemotherapy as measured in comparison
with chemotherapy based upon other alkylating agents allows the
recommendation of the former regimen as a control arm in future
chemotherapy research. Important questions remain unanswered
in particular that of the optimal dosage of cisplatin and the choice
of drugs it should be correctly associated with.
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Figure 1 Odds ratio and 95% confidence interval of being a non-responder for patients treated with a CDDP-containing regimen (P < 10–5). Results are
expressed as individual and overall ORs, vertical bar, and their respective 95% confidence intervals, horizontal bar. ORs lower than 1 indicate a reduction of risk
of being non-responders with a cisplatin-containing regimen (overall OR (95%CI): 0.74 (0.85–0.64). Test for heterogeneity: Q = 46.01; df: 18; P = 0.001Meta-analysis of cisplatin in SCLC 13
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Figure 2 Odds ratio and 95% confidence interval of mortality at 6 months for patients treated with a CDDP-containing regimen (symbols as in Figure 1; 
P = 0.03). Test for heterogeneity: Q = 21.68; df: 18; P = 0.25
Figure 3 Odds ratio and 95% confidence interval of mortality at 1 year for patients treated with a CDDP-containing regimen (symbols as in Figure 1; 
P = 0.002). Test for heterogeneity: Q = 26.47; df: 18; P = 0.10
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